Metric Finance
LearnFAQ
LearnFAQ

Learn / OVID

NASDAQ: OVID

Ovid Therapeutics (OVID) stock, explained like you're 5

Ovid Therapeutics trades on the Nasdaq under the ticker OVID. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 480 million dollars.

Ticker
OVID
Exchange
Nasdaq
Sector
Healthcare
Industry
Pharmaceutical Preparations
Size
Small cap, about 480 million dollars

Is Ovid Therapeutics a small, medium or large cap company?

No. Ovid Therapeutics is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 480 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Ovid Therapeutics makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves OVID stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Ovid Therapeutics (NasdaqCM:OVID) Stock Forecast & Analyst Predictions (Simply Wall Street)
  • What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now? (Yahoo Finance)
  • OVID Forecast Price Target Prediction for 2027 (TradingView)
  • OVID Initiates Coverage On Wolfe Research Rating Set to Outpe (GuruFocus)
  • OVID Apr 2027 2.000 call (OVID270416C00002000) Stock Price, News, Quote & History (Yahoo! Finance Canada)

Follow OVID in your daily brief

Each trading day at 5 PM ET we post what happened to Ovid Therapeutics and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow OVID

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Ovid Therapeutics stock

What does Ovid Therapeutics do?

Ovid Therapeutics trades on the Nasdaq under the ticker OVID. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 480 million dollars.

What is the ticker symbol for Ovid Therapeutics?

Ovid Therapeutics trades under the ticker OVID on the Nasdaq.

What is Ovid Therapeutics's market cap?

Ovid Therapeutics is a small cap stock with a market cap of about 480 million dollars.

How does Ovid Therapeutics make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves OVID stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow OVID stock every day?

Add OVID to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow OVID daily

A free brief on Ovid Therapeutics and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • NVS · Novartis AG
  • AZN · Astrazeneca PLC
  • NVO · Novo Nordisk A S
  • VRTX · Vertex Pharmaceuticals Inc / Ma

Similar stocks

  • NVSNovartis AG
  • AZNAstrazeneca PLC
  • NVONovo Nordisk A S
  • VRTXVertex Pharmaceuticals Inc / Ma

Compare OVID: OVID vs NVS, OVID vs AZN, OVID vs NVO

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed